Sarravis® Formulations

To Dr. Gowey, one of the unfortunate aspects of herbal medicine-making is a requirement for high amounts of plant biomass—even to make small amounts of medicines. Therefore, with a desire to serve innumerable numbers of patients, Dr. Gowey set out to develop potential drug extracts from the Sarracenia spp. that were very efficient, able to provide the essence of the plants to the patient (with very little biomass). She feels she has accomplished this with Sarravis®. Any merit Sarravis® may have with respect to supporting cell infrastructure, as is Dr. Gowey’s theory (such as in affecting disulfide bonds due to presence of free thiols), has yet to be demonstrated via in vitro (or other) studies: all of the Sarravis® formulations are available for research and/or development as it relates to drug approval processes. 

Dr. Gowey assumes that downstream effects of the Sarravis® thiols may be upon sulfhydryl oxidase, RNA interference cofactors (such as DICER and SLICER), and p53. This assumption is based on examination of personal subjective findings and objective genomic expression changes upon use of the Sarravis® extracts. Please refer to her paper, “Commentary on HPV Integration, Free Thiols, and the RNAi: Lessons from a Carnivorous Plant (available on the publication page) for more information.